STAT3 and neoplasm: Thus, targeting of either STAT3, or c-Rel, or PI3Kγ reprogram myeloid cells towards an anti-tumour phenotype resulting in the sculpting of a TME towards the support of cytotoxic T cell response and restricting tumour progression in preclinical models of solid cancers [69–73].